ABP-671 clinical trials
Also written ABP-671.
How each study uses ABP-671 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ABP-671 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABP-671
- 6
Studies by the year they started
8 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Atom Therapeutics Co., Ltd (4) · Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ABP-671.
- Oct 2027Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and HyperuricaemiaPhase 2 · Atom Therapeutics Co., Ltd
Studies
Open first, then newest update. How each study uses ABP-671 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and HyperuricaemiaRecruitingPhase 2Atom Therapeutics Co., LtdNCT07323095Written as ABP-671 Group
- Drug-Drug Interaction Study of ABP-671 in Gout PatientsCompletedPhase 1Atom Therapeutics Co., LtdNCT07367971Written as ABP-671 plus allopurinol
- Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With GoutCompletedPhase 2/3Atom Therapeutics Co., LtdNCT05818085Written as ABP-671
- Extension Study of ABP-671 in Participants With GoutTerminatedPhase 2/3Atom Therapeutics Co., LtdNCT06276556Written as ABP-671
- A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or HyperuricemiaCompletedPhase 2Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.NCT04638543Written as ABP-671
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy SubjectsCompletedPhase 1Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.NCT03906006Written as ABP-671
- Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy SubjectsCompletedPhase 1Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.NCT04303039Written as ABP-671
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671CompletedPhase 1Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.NCT04060173Written as ABP-671
What changed recently
From the registry's own updates since Oct 15, 2026.